|Day Low/High||0.56 / 0.57|
|52 Wk Low/High||1.53 / 2.72|
Here's a technical look at how to trade some of the most active stocks on the market right now.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
These low-dollar biotech stocks are making big moves Monday -- in opposite directions.
Company Will Host Conference Call Monday, September 26th at 9:00am EDT
Pain Therapeutics Announced today that an FDA Advisory Committee Meeting for REMOXY® is Not Needed and No Change to September 25, 2016 PDUFA Date
No Change to September 25th PDUFA Date
FDA's Tentative Date for Advisory Committee Meeting is August 5, 2016 and No Change to PDUFA Date of September 25, 2016
REMOXY NDA Has Priority Review
Focus in 2016 Will be on REMOXY, Fiscal Discipline and Advancing Pipeline
Focus Remains on NDA Resubmission to FDA, Targeted for Q1 2016
The most recent short interest data has been released by the NASDAQ for the 05/29/2015 settlement date, which shows a 650,044 share increase in total short interest for Pain Therapeutics Inc , to 3,037,711, an increase of 27.23% since 05/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Conference Call Tomorrow, Tuesday, at 4:30 p.m. Eastern Time